Use of secondary preventive medications after the first attack of acute coronary syndrome

European Journal of Preventive Cardiology

Volumn 14, Issue 3, 2007, Pages 386-391

  Salomaa, Veikko ^a   Pääkkönen, Rauni ^a   Hämäläinen, Helena ^b   Niemi, Marja ^a   Klaukka, Timo ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

acute coronary syndrome; beta blockers; epidemiology; medications; statins

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMALE; FINLAND; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; REIMBURSEMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; CORONARY DISEASE; FEMALE; FINLAND; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RESEARCH DESIGN; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 34250647421     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000244573.10229.6e     Document Type: Article

References (26)

1. Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 20(342):145–153.
3. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 26: 1730–1737.
4. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38: 1581–1583.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl 1):S1–S78.
6. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001.
7. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–189.
8. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140–2144.
9. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004; 25: 1990–1997.
10. Pajunen P, Pääkkönen R, Juolevi A, Hämäläinen H, Keskimäki I, Laatikainen T, et al. Trends in fatal and non-fatal coronary heart disease events in Finland during 1991-2001. Scand Cardiovasc J 2004; 38: 340–344.
11. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 132–137.
12. SAS Institute Inc. (1999) Users guide, statistics, Version 8. Cary, North Carolina: SAS Institute; 1999.
13. Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients or = 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735–1743.
14. Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol 1999; 34: 1388–1394.
15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497.
16. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA, National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998; 280: 623–629.
17. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–1158.
18. Newby LK, LaPointe NMA, Chen AY, Kramer JM, Hammil BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203–212.
19. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, Hlatky MA. For the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 2006; 144: 229–238.
20. Wei L, Ebrahim S, Bartlett C, Davey PG, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821–824.
21. Feringa HHH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47: 1182–1187.
22. Coronary Drug Project Investigators. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038–1041.
23. Green A, Hirsch NC, Pramming SK. The changing world demography of type 2 diabetes. Diabetes Metab Res Rev 2003; 19: 3–7.
24. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 2002; 18 (Suppl 3):S21–S26.
25. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 2002; 18 (Suppl 3):S3–S8.
26. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73–78.